Chronic Obstructive Pulmonary Disease: Recent Advances and Controversies in Inhaler Therapies

Affiliations

Comment

Zhou Zhang et al. Am J Respir Crit Care Med. 2018.

. 2018 Apr 1;197(7):944-946.

doi: 10.1164/rccm.201704-0833RR.

¹ Pulmonary and Critical Care Medicine Fellowship, Cedars-Sinai Medical Center, Los Angeles, California.

No abstract available

Comment on

A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.
Calzetta L, Rogliani P, Matera MG, Cazzola M. Calzetta L, et al. Chest. 2016 May;149(5):1181-96. doi: 10.1016/j.chest.2016.02.646. Epub 2016 Feb 26. Chest. 2016. PMID: 26923629
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE; SUMMIT Investigators. Vestbo J, et al. Lancet. 2016 Apr 30;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1. Epub 2016 Apr 28. Lancet. 2016. PMID: 27203508 Clinical Trial.
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Singh D, et al. Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1. Lancet. 2016. PMID: 27598678 Clinical Trial.